News

Understanding the Recent Options Trends at CrowdStrike Holdings

Understanding the Recent Options Trends at CrowdStrike Holdings

Analyzing Recent Options Activities of CrowdStrike Holdings

Investors are closely watching CrowdStrike Holdings (NASDAQ: CRWD) as a shift in options activity is observed. A bearish sentiment has emerged among large investors, indicating caution in the market. Tracking options records reveals significant movements that should not go unnoticed by market participants. While the identities of these investors remain undisclosed, such drastic changes in options usually indicate substantial upcoming developments.

Volume and Activity Highlights

Recent scans of options activity have uncovered several noteworthy transactions related to CrowdStrike Holdings. A total of 8 significant movements have been identified today, marking a level of activity beyond the ordinary. The investors are showing a pronounced bearish outlook, with 75% favoring puts compared to only 12% leaning towards calls. Specifically, the put transactions total around $266,798, while call options account for about $82,996.

Price Range Expectations

Inspecting the volume and open interest of these options gives us insight into market sentiments. Notably, it appears that significant investors, often referred to as 'whales,' have been focusing on targeting a price range from $270.0 to $570.0 for CrowdStrike Holdings over the previous three months. This suggests that investors are strategically betting on the stock's price movement within this spectrum.

Insights from Volume and Open Interest Trends

By analyzing volume and open interest, we can gain critical insights into Liquidity and investor interest for CrowdStrike Holdings’s options at various strike prices. The data reveals essential trends in both calls and puts, shedding light on investor behaviors and market expectations over the last month.

Snapshot of Option Volume and Interest

Key data related to CrowdStrike Holdings includes put and call volume which signifies broader trends in the market. These indicators serve as essential tools when evaluating options profitability and interest levels, providing a comprehensive view of recent trading activities.

Notable Options Activity Breakdown

Here’s a closer look at the options activity:

  • CRWD PUT: A notable sweep was seen with a bearish sentiment marked by a total trade price amounting to $90.1K, targeting a strike price of $467.50 with an expiration date set for January 9, 2026.
  • CRWD PUT: Another trade, also bearish, indicated a strong move with a trade price of $50.1K, targeting $472.50 for January 2, 2026.
  • CRWD CALL: Contrastingly, some bullish trading was observed; however, it is minimal compared to bearish options. The sentiment is still cautious in this regard.

About CrowdStrike Holdings

CrowdStrike Holdings is making significant waves in the cybersecurity domain. This cloud-based firm specializes in next-generation security solutions, with its core product being the Falcon platform, which allows enterprises to identify and respond to security threats effectively. Founded in 2011, the company went public in 2019 and has gained considerable traction in its sector.

Current Performance Overview

At present, CrowdStrike Holdings is trading at a price of $477.91, reflecting a marginal increase of 0.17%. With a trading volume of 87,312, the stock seems to hover around its average performance. Additionally, Relative Strength Index (RSI) indicators suggest that the stock may be moving towards an oversold condition, indicating potential buying opportunities on the horizon.

Expert Analysis and Price Predictions

In the past month, analysts have shared their insights regarding CrowdStrike Holdings. They have settled on an average price target of $584.2, reflecting confidence in the company's future growth. Different analysts have varying opinions:

  • One analyst from BTIG has recently lowered their target but maintains a Buy rating at $640.
  • Goldman Sachs continues to support the stock with a target of $564 and a Buy rating intact.
  • Meanwhile, Morgan Stanley remains neutral with an Equal-Weight rating, targeting a price of $537.

This unanimous interest from analysts suggests a positive outlook for CrowdStrike Holdings as it continues to grow in the cybersecurity market.

Frequently Asked Questions

What is the recent sentiment among investors for CrowdStrike Holdings?

Recent options data shows a predominantly bearish sentiment among investors, with 75% favoring puts.

What is the price range that investors are targeting for CRWD?

Investors have been focusing on a price range from $270.0 to $570.0 for CrowdStrike Holdings over recent months.

What key information is revealed by the volume and open interest?

Volume and open interest provide insights into liquidity and can indicate investor interest or sentiment regarding certain strike prices.

How is CrowdStrike Holdings positioned in the current market?

CrowdStrike Holdings is currently trading at approximately $477.91 with minor fluctuations in market performance.

What do analysts predict for CrowdStrike's future growth?

Analysts have set average price targets above the current price, indicating optimism for the company’s growth prospects.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 7

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 6

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 8

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 8

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 11

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 12

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 5

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 12

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 11

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading

Top 5 Most Recently Viewed Articles

A Closer Look at Marvell Tech's Upcoming Earnings Release

Updated Category News Views 184

Marvell Tech's Expected Earnings Release Marvell Tech (NASDAQ: MRVL) is set to announce its latest quarterly earnings in December. As investors await this critical financial moment, a brief review of what to expect can shed light on potential impacts and opportunities. Analysts' Earnings Projections Analysts forecast that Marvell Tech will achieve an earnings per share...

Continue Reading
Banijay Group's Recent Share Transactions Update and Insights

Updated Category News Views 222

Recent Share Transactions Overview Banijay Group N.V. (ISIN: NL0015000X07, Bloomberg: BNJ NA, Reuters: BNJ.AS) has reported on its recent share transactions, showcasing the buying and selling activities from the period of September 22 to September 26. Understanding Share Transactions During this timeframe, a mix of buying and selling occurred within the company’s...

Continue Reading
Strategic Growth for Voyageur Mineral Explorers via New Offering

Updated Category News Views 143

Voyageur Mineral Explorers Corp. Secures Massive Funding Voyageur Mineral Explorers Corp. (CSE: VOY) has recently made headlines by completing a significant brokered offering, raising $37.5 million. This financial boost comes at a crucial time for the Company as it seeks to expand its operations and investments in the mineral exploration sector. The offering was executed...

Continue Reading
Applied Materials Faces Challenges Amid Weak Outlook and Stocks

Updated Category News Views 114

Applied Materials Inc. Stock Performance Applied Materials Inc. (NASDAQ: AMAT) recently experienced a noticeable decline in its stock value as the company shared its financial results. After the market closure, the organization revealed its third-quarter earnings, leading to significant concern among investors. The stock's value tumbled, reflecting the market's reaction...

Continue Reading
VFC Class Action Demands Attention: Key Details for Investors

Updated Category News Views 192

Understanding the VFC Class Action Lawsuit Investors in V.F. Corporation, commonly known as VFC, should pay close attention to a pending class action lawsuit that could have significant implications. The law firm Faruqi & Faruqi, a reputable name in securities litigation, has stepped forward to represent affected investors. They are drawing attention to a critical...

Continue Reading